Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia
NCT01723644 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 286
Last updated 2017-05-31
Summary
CLINPCT study is a prospective, randomized, controlled, open intervention clinical trial including adult patients admitted in the emergency department with community-acquired pneumonia. The objective of this clinical trial is to compare two strategies: clinical reassessment and procalcitonin guided diagnostic and therapeutic strategy in patients with community-acquired pneumonia. In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America (Temperature ≤37.8°C, Heart rate ≤100 beats/min, Respiratory rate ≤24 breaths/min, Systolic blood pressure ≥90 mm Hg, Arterial oxygen saturation ≥90% or pO2 ≥60 mm Hg on room air). In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
Conditions
- Community-acquired Pneumonia
Interventions
- OTHER
-
the clinical reassessment arm
In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
- OTHER
-
the procalcitonin arm
In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Principal Investigators
-
Emmanuel Montassier · Nantes University Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-10-31
- Primary Completion
- 2015-04-30
- Completion
- 2017-05-31
Countries
- France
Study Locations
More Related Trials
-
Procalcitonin Versus C-reactive Protein to Guide Therapy in Community Acquired Pneumonia
NCT01018199 ·Status: WITHDRAWN ·Phase: NA
-
PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT
NCT04158804 ·Status: COMPLETED ·Phase: NA
-
Procalcitonin Antibiotic Consensus Trial (ProACT)
NCT02130986 ·Status: COMPLETED ·Phase: NA
-
An Antibiotic Protocol Guided by a Multimodal Approach in AECOPD With Pneumonia in Intensive Care
NCT06301841 ·Status: RECRUITING ·Phase: NA
-
Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)
NCT02173613 ·Status: TERMINATED ·Phase: NA
-
POCT PCT in Outpatient LRTI
NCT05380869 ·Status: COMPLETED ·Phase: NA
-
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT04682899 ·Status: UNKNOWN ·Phase: PHASE3
-
Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis
NCT06977165 ·Status: NOT_YET_RECRUITING
-
Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia
NCT03146182 ·Status: UNKNOWN ·Phase: NA
-
Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients
NCT02600806 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Characteristics and Microbiology of Community-Acquired Pneumonia
NCT03098914 ·Status: UNKNOWN
-
Use Of Procalcitonin Level For Guidance of The Treatment of Suspected Community Acquired Pneumonia
NCT00914550 ·Status: COMPLETED
-
Procalcitonin as a Marker of Bacterial Pneumonia
NCT00415753 ·Status: COMPLETED ·Phase: NA
-
Antibiotics in Patients With Acute Respiratory Tract Infection With Procalcitonin as Parameter
NCT00688610 ·Status: COMPLETED ·Phase: PHASE2
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations
NCT05854901 ·Status: UNKNOWN ·Phase: NA
-
Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis
NCT03058718 ·Status: COMPLETED ·Phase: NA
-
An Algorithm to Decide on Antibiotic Prescription in Lower Respiratory Tract Infection in Primary Care
NCT03191071 ·Status: COMPLETED ·Phase: NA
-
Assessing Effectiveness of Community Acquired Pneumonia Treatment by Continuous Pneumonia Severity Score
NCT04135183 ·Status: UNKNOWN ·Phase: NA
-
Procalcitonin Guided Antibiotic Therapy and Hospitalisation in Patients With Lower Respiratory Tract Infections: The "ProHOSP" Study
NCT00350987 ·Status: COMPLETED ·Phase: NA
-
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
NCT00273676 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of a Serum PRO-CT Guided Treatment and the Recommended Antibiotic Treatment for COPD
NCT01125098 ·Status: COMPLETED
-
Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections
NCT01660204 ·Status: COMPLETED ·Phase: NA
-
Customized Antibiotic Treatment Duration Among Hospitalized Patients With Moderately Severe Community-Acquired Pneumonia
NCT05903352 ·Status: RECRUITING ·Phase: PHASE3
-
Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward
NCT06229288 ·Status: RECRUITING ·Phase: PHASE3